Can the FDA-approved drug Eylea HD be used to treat my neovascular AMD?
Eylea HD is a higher-dose formulation of aflibercept, a type of anti-VEGF medication. It works by blocking a protein called VEGF that fuels abnormal blood vessel growth and leakage in the eye. The U.S. Food and Drug Administration (FDA) has specifically approved Eylea HD for treating neovascular (wet) age-related macular degeneration (nAMD) 6. This means it is a recognized treatment option for your condition.
What the research says
The FDA approval of Eylea HD for nAMD is based on clinical trials showing it can improve vision and reduce retinal fluid 6. Aflibercept, the active drug in Eylea HD, has been studied extensively. A 2012 review noted that aflibercept was a new, effective anti-VEGF agent for nAMD 9. More recent research confirms that biosimilar versions of aflibercept match the original drug in safety and effectiveness for nAMD 3. However, long-term anti-VEGF therapy, including with aflibercept, is not a cure. Studies show that after 5 years of treatment, 40-50% of eyes develop subretinal fibrosis (scarring), which can lead to vision loss 7. Additionally, some patients may have persistent inflammation or incomplete response due to other immune pathways 5. Despite these challenges, anti-VEGF therapy remains the standard of care for nAMD 9.
What to ask your doctor
- Is Eylea HD a good option for my specific type and stage of neovascular AMD?
- How often would I need injections of Eylea HD compared to other anti-VEGF drugs?
- What are the possible side effects and risks of Eylea HD, including inflammation or retinal scarring?
- Are there any other treatments I should consider, such as other anti-VEGF drugs or combination therapies?
- How will we monitor my response to treatment, and what signs of complications should I watch for?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.